Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Holdings Decreased by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC decreased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 168,015 shares of the biopharmaceutical company’s stock after selling 2,385 shares during the period. Motley Fool Wealth Management LLC owned approximately 0.18% of Ultragenyx Pharmaceutical worth $9,333,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. nVerses Capital LLC bought a new position in Ultragenyx Pharmaceutical during the second quarter valued at about $33,000. UMB Bank n.a. lifted its holdings in Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 352 shares during the last quarter. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at about $43,000. Values First Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $56,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $107,000. 97.67% of the stock is currently owned by institutional investors.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,465 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the sale, the chief financial officer now directly owns 92,301 shares in the company, valued at approximately $4,869,800.76. This represents a 7.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on RARE shares. Cantor Fitzgerald restated an “overweight” rating and set a $116.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Royal Bank of Canada restated an “outperform” rating and issued a $77.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. Finally, HC Wainwright upped their price objective on shares of Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $87.46.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $46.67 on Wednesday. The company has a market capitalization of $4.31 billion, a PE ratio of -7.21 and a beta of 0.56. The company’s 50 day moving average price is $51.63 and its 200 day moving average price is $48.79. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. The business had revenue of $139.49 million for the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. Ultragenyx Pharmaceutical’s revenue was up 42.3% on a year-over-year basis. During the same period in the previous year, the company posted ($2.23) EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.2 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.